Unknown

Dataset Information

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.


ABSTRACT:

Aims

Renal disease is a frequent comorbidity of type 2 diabetes mellitus (T2DM) and an important factor complicating the choice of glucose-lowering drugs. The aim of this analysis was to evaluate the efficacy and safety of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin (5 mg/day) in mono, dual or triple oral glucose-lowering regimens in subjects with T2DM and mild or moderate renal impairment (RI).

Methods

In this pooled analysis of three 24-week, placebo-controlled, phase 3 trials, subjects with mild (estimated glomerular filtration rate (eGFR) 60-<90 ml/min/1.73 m(2) , n = 838) or moderate RI (30-<60 ml/min/1.73 m(2), n = 93) were compared with subjects with normal renal function (≥90 ml/min/1.73 m(2), n = 1212).

Results

Subjects with RI were older, had long

SUBMITTER: Groop PH 

PROVIDER: S-EPMC4288982 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature